ABEONA THERAPEUTICS

ABEONA THERAPEUTICS

Share · US00289Y2063 · ABEO (LSSI)
Overview
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of ABEONA THERAPEUTICS
Analyst Grade Summary
gauge-img
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell
0
6
3
0
0
No Price
28.04.2026 05:27
Current Prices from ABEONA THERAPEUTICS
ExchangeTickerCurrencyLast TradePriceDaily Change
XDQU: Quotrix
Quotrix
ATIRSD063.DUSD
EUR
28.04.2026 05:27
4,57 EUR
-
XNAS: NASDAQ
NASDAQ
ABEO
USD
27.04.2026 23:15
5,44 USD
0,05 USD
+0,93 %
IEXG: IEX
IEX
ABEO
USD
27.04.2026 19:59
5,35 USD
-0,04 USD
-0,83 %
XLON: London
London
0H7R.L
USD
27.04.2026 17:53
5,35 USD
-0,04 USD
-0,74 %
XDUS: Düsseldorf
Düsseldorf
ATIRSD063.DUSB
EUR
27.04.2026 06:12
4,47 EUR
-
XHAM: Hamburg
Hamburg
ATIRSD63.HAMB
EUR
23.04.2026 06:13
4,78 EUR
-
Share Float & Liquidity
Free Float 74,45 %
Shares Float 42,47 M
Shares Outstanding 57,05 M
Company Profile for ABEONA THERAPEUTICS Share
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.

Company Data

Name ABEONA THERAPEUTICS
Company Abeona Therapeutics Inc.
Symbol ABEO
Website https://www.abeonatherapeutics.com
Primary Exchange LSSI Lang & Schwarz
ISIN US00289Y2063
Asset Class Share
Sector Healthcare
Industry Medical - Pharmaceuticals
CEO Vishwas Seshadri
Market Capitalization 257 Mio
Country United States of America
Currency EUR
Employees 0,1 T
Address 1330 Avenue of the Americas, 10019 Cleveland
IPO Date 2018-01-29
Dividends from 'ABEONA THERAPEUTICS'
Ex-Date Dividend per Share
15.03.2022 0,01 USD
31.03.2000 0,59 USD

Stock Splits

Date Split
05.07.2022 1:25
24.10.2014 1:50
05.06.2006 1:5
18.06.1998 1:20
05.06.1998 1:20
16.04.1992 1:2

ID Changes

Date From To
19.06.2015 PTBI ABEO

Ticker Symbols

Name Symbol
Düsseldorf ATIRSD063.DUSB
Frankfurt PCJ.F
Hamburg ATIRSD63.HAMB
London 0H7R.L
NASDAQ ABEO
Quotrix ATIRSD063.DUSD
More Shares
Investors who hold ABEONA THERAPEUTICS also have the following shares in their portfolio:
BPCE ASSUR. 25/UND. FLR
BPCE ASSUR. 25/UND. FLR Bond
DZ BANK IS.A2623 VAR
DZ BANK IS.A2623 VAR Bond